NewsDialy
Venture capitalists are increasingly investing in osteoporosis drug development following new guidance from the Food and Drug Administration.
The Federal agency’s updated rules have prompted pharmaceutical companies to resume research into treatments for brittle bones, a field that had previously faced significant hurdles.
Historically, developing drugs for osteoporosis has been challenging due to safety concerns and regulatory barriers.
However, the recent FDA guidance has shifted the landscape, drawing new financial attention to the sector. STAT+ highlights this trend in its coverage of the biotech market.
Keep reading